Please ensure Javascript is enabled for purposes of website accessibility

Novavax's COVID-19 Vaccine Gets $388 Million in Funding, Biggest Amount Yet from CEPI

By Keith Speights - May 12, 2020 at 10:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big investment from CEPI will enable the biotech to fund clinical development of its COVID-19 vaccine candidate and rapidly scale up production.

Novavax (NVAX -5.13%) announced Monday evening that the Coalition for Epidemic Preparedness Innovations (CEPI) is investing up to $384 million to fund the clinical development of experimental vaccine NVX-CoV2373 targeting the novel coronavirus that causes COVID-19. In March, Novavax received $4 million from CEPI for its COVID-19 vaccine program. 

A big deal

CEPI was formed in 2017 as a partnership between the public sector and the private sector, including philanthropic and civil society organizations, to develop vaccines to fight epidemics. The organization has funded nine experimental COVID-19 vaccines with a goal to advance these vaccine candidates into clinical testing as rapidly as possible. 

Coronavirus vaccine bottles

Image source: Getty Images.

The total funding of up to $388 million for Novavax's COVID-19 vaccine program represents CEPI's largest investment so far. CEPI CEO Richard Hatchett said that "it is vital that we invest now to boost manufacturing capacity, so that our partners have the ability to produce vaccines at a global scale."

The additional $384 million of funding will help Novavax advance the clinical studies for its NVX-CoV2373 vaccine. This funding will also enable the company to rapidly scale up production of the vaccine and its proprietary Matrix-M adjuvant, which could boost levels of neutralizing antibodies and lead to better immune responses.

What's next

Novavax plans to begin a phase 1/2 clinical study evaluating its experimental COVID-19 vaccine this month. It will also expand its production capabilities to manufacture up to 100 million vaccine doses by the end of this year. In addition, Novavax will use the CEPI funding to access large-scale manufacturing capacity across the world with the goal of producing over 1 billion doses of its vaccine in 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$51.06 (-5.13%) $-2.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.